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T Nakano1, AP Chahinian2, M Shinjo1, A Tonomura1, M Miyake1, N Togawa1, K Ninomiya1 and K Higashino1
'Third Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663, Japan; 2Department of Neoplastic Diseases, Mount Sinai Medical
Center, New York, New York
Summary The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural
mesothelioma. The serum levels of IL-6, C-reactive protein, a,-acid glycoprotein and fibrinogen were significantly higher in mesothelioma
than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins.
We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The
level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higherthan in the pleural fluid of patients with adenocarcinoma,
and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were
found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with
mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as
similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid
argues against a diagnosis of adenocarcinoma.
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The pleotrophic cytokine interleukin 6 (IL-6) plays a significant
role in the inflammatory processes that are associated with certain
pathological conditions, including neoplasia. The inflammatory
reaction consists oflocal and systemic responses, such as vasodila-
tion, increase of vascular permeability, cellular infiltration, fever,
leucocytosis and increases in acute-phase protein (APP) levels.
Mesothelioma cells and cell lines have been reported to produce
IL-6 (Higashihara et al, 1992; Schmitter et al, 1992; Bielefeldt-
Ohmann et al, 1995a), and the related thrombocytosis is the most
frequent paraneoplastic syndrome associated with this neoplasm,
as first described by Chahinian and Pajak (1982). IL-6 interacts
with several target cells to initiate a variety ofbiological activities,
including the stimulation of hepatocytes to produce APPs, e.g. C-
reactive protein (CRP), alpha-l-antitrypsin (AAT), alpha-l-acid
glycoprotein (AGP) and fibrinogen (Nijsten et al, 1987; Geiger et
al, 1988; Castell et al, 1990), the stimulation of megakaryocyto-
poiesis (Ishibashi et al, 1989) and the stimulation of fibroblasts to
produce collagen and glycosaminoglycan (GAG) (Duncan and
Berman, 1991). High concentrations ofIL-6 have been detected in
the pleural fluid of patients with malignant mesothelioma (Monti
et al, 1994), but, to our knowledge, there have been no detailed
reports of a relationship between IL-6 and clinical inflammatory
parameters, and the significance of IL-6 to the clinical pathology
ofthis neoplasm is still unclear.
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Histopathologically, the differentiation of malignant pleural
mesothelioma and pleural metastases of adenocarcinoma of the
lung is still difficult (Wirth et al, 1991) and frequently requires
special immunohistological staining using polyclonal (Donna et
al, 1989) or monoclonal (Stahel et al, 1988; Wright et al, 1989)
anti-mesothelial antibodies. Clinically, the differentiation is
important to ensure appropriate treatment.
In this study, we investigated the clinical responses to IL-6
production in patients with malignant pleural mesothelioma and
the differences in levels of IL-6 and APPs in patients with
mesothelioma, with lung adenocarcinoma with acytology-positive
pleural effusion and in patients with tuberculous pleurisy.
PATIENTS AND METHODS
Patients
We studied 25 patients with newly diagnosed malignant pleural
mesothelioma, 17 patients with newly diagnosed lung adenocarci-
noma and cytology-positive pleural effusion and 15 patients with
tuberculous pleurisy. The diagnosis ofmesothelioma was made by
histological and immunohistochemical analysis of pleural biopsy
specimens and by cytological examination of the pleural fluids,
which was supported by the biochemical studies on GAG in
tumour tissue, as previously reported (Nakano et al, 1986a). The
diagnosis of lung adenocarcinoma with cytology-positive pleural
effusion was established histologically by studying tumour speci-
mens obtained by bronchoscopy or percutaneous needle biopsy
andby cytological examination ofthepleural fluids. The diagnosis
of tuberculous pleurisy was made by pathological findings in
closed biopsied pleural samples or by detecting mycobacterium
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Table 1 Interleukin 6 and acute-phase proteins levels in serum
Disease IL-6 CRP AGP AAT Fibrinogen Pre-albumin
(pg ml-1) (mg dl-') (mg di-1) (mg d-1) (mg dl-' mg dl-'
(< 4)a (< 0.3)a (32_98)a (170-274)a (220470)a (21-43)a
Malignant pleural 28.7 1 7.8 1 205 1 402 1 522 1 10.4
mesothelioma (n = 25) (4.0-322.0) (0.2-26.5) (87-513) (207-856) (310-1106) (1.0-44.6)
P< 0.05 P< 0.01 P< 0.01 P< 0.01 P< 0.05 NS
Lung adenocarcinoma with 6.3 0.6 119 250 353 7.4
cytology-positive pleural effusion (n = 17) (6.3-40.6) (0.1-6.0) (55-174) (219-411) (247-560) (0.7-17.1
aNormal value. IL-6, interleukin 6; CRP, C-reactive protein; AGP, alpha-1 acid glycoprotein; AAT, alpha-1 antitrypsin. Values are expressed as median (range).
tuberculosis in culture fluid and/or by a good response to anti-
tuberculosis chemotherapy.
Methods
Serum and pleural fluid samples were obtained before
chemotherapy and stored at - 60°C until analysis.
The concentrations of IL-6 (Toray, Tokyo, Japan) and tumour
necrosis factor-a (TNF-ca) (Otsuka, Tokyo, Japan) were measured
using the commercially available ELISA kit. The limit ofdetection
of the tests was 4.0 pg ml' for IL-6 and 3.7 pg ml-' for TNF-a
(lower levels were considered undetectable); the interassay varia-
tion coefficients were 3.8% and 7.1% respectively. In age-matched
normal subjects, IL-6 and TNF-a were undetectable in the serum
or at the limit of detection of the assay. Determinations of CRP
(Eiken-Kagaku, Tokyo, Japan), adenosine deaminase (ADA)
(Maruno, Osaka, Japan), fibrinogen (International Reagents,
Kobe, Japan), AAT, AGP and pre-albumin concentrations
(Behringwerke, Germany) were also performed using commer-
cially available kits. In accordance with the information provided
by our institution, the normal values of CRP, ADA, fibrinogen,
AGP, AAT and pre-albumin in serum are <0.3 mg dl-',
9.2-19.1 IU l-', at 37°C, 220-470 mg dl-', 32-98 mg dl-', 170-
274 mg dl-' and 21-43 mg dl-1 respectively. The normal range
for platelet counts is 120-280 x 109 1-'. Thrombocytosis was
defined as a platelet count above 400 x 1091-'.
Statistical analysis
Statistical analysis was performed using the Mann-Whitney U-
test. Survival was calculated from the start oftreatment to death or
the date ofthe last follow-up using the actuarial method ofKaplan
and Meier. A P-value ofless than 0.05 was considered to be statis-
tically significant.
RESULTS
IL-6, TNF-a and acute-phase proteins in serum
The levels of serum IL-6, CRP, AGP, ATT and fibrinogen in
patients with mesothelioma were significantly higher than those in
patients with lung adenocarcinoma and pleural effusion, whereas
the difference in pre-albumin levels was not significant (Table 1).
A marked increase in the level of IL-6 (over 100 pg ml-') was
detected in 6 out ofthe 25 cases ofmesothelioma (Figure 1). There
were significant positive correlations between IL-6 levels and the
levels ofCRP (Figure 2, P < 0.01, r = 0.69), fibrinogen (Figure 2,
P<0.05
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Figure 1 Comparison of IL-6 values in serum and in pleural fluid of patients
with malignant mesothelioma, lung adenocarcinoma with cytology-positive
pleural effusion and tuberculous pleurisy
P < 0.01, r = 0.71), AAT (Figure 3, P < 0.01, r = 0.75) and AGP
(Figure 3, P < 0.05, r = 0.55) in the serum. TNF-x levels in the
serum of patients with mesothelioma or lung adenocarcinoma
were undetectable or very low.
IL-6, TNF-a and acute-phase proteins in pleural fluid
The level of IL-6 in the pleural fluid of mesothelioma patients was
markedly higherthan that in their serum(Figure 1). Thepleural fluid
level was about 60-1400 times higher than the serum level, with a
tendency for the serum level to correlate with the pleural fluid level,
although the relationship was not statistically significant. The level
of IL-6 in the pleural fluid of mesothelioma patients was signifi-
cantly higher than that in the pleural fluid of lung adenocarcinoma
patients. An even more significant increase in IL-6 levels was found
in tuberculous pleural fluid (Table 2 and Figure 1).
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Figure 2 Relationship between IL-6 level and CRP level or fibrinogen level
in the serum of patients with malignant pleural mesothelioma. Individual
values are indicated for CRP (0, r= 0.69, P< 0.01) and fibrinogen
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Figure 3 Relationship between IL-6 level and alpha-1 antitrypsin level or
alpha-1 acid glycoprotein level in the serum of patients with malignant pleural
mesothelioma. Individual values are indicated for alpha-1 antitrypsin (0,
r= 0.75, P< 0.01) and alpha-1 acid glycoprotein (A, r= 0.55, P< 0.05
The CRP level in the pleural fluid ofmesothelioma patients was
significantly higher than that in lung adenocarcinoma patients.
Tuberculous pleural fluid also contained very high levels ofAPPs,
similar to those in mesothelioma pleural fluid, as well as signifi-
cantly increased levels ofADA.
In contrast to the marked increase in IL-6 levels, TNF-cx levels
in pleural fluid were undetectable or very low.
Thrombocytosis and IL-6
Thrombocytosis (platelets >400 x 1091-1) was observed in 12 ofthe
25 cases of malignant mesothelioma (48%), 5 of the 15 cases of
tuberculous pleurisy (33%) and 2 of the 17 cases of lung adeno-
carcinoma with pleural effusion (12%). The platelet counts at diag-
nosis in patients with mesothelioma were much higherthan those in
patients with lung adenocarcinoma (P < 0.01). In addition, patients
with tuberculous pleurisy had significantly higher platelet counts
than patients with lung adenocarcinoma. There was no significant
difference in platelet count between mesothelioma patients and
patients with tuberculous pleurisy. Serum IL-6 levels correlated
significantly with platelet counts (Figure 4, P < 0.01, r = 0.76).
Four patients with mesothelioma and ten patients with tuberculous
pleurisy had extremely high levels of IL-6 (> 10000 pg ml-'). The
maximum platelet counts in the four mesothelioma patients with
high serum IL-6 levels were markedly increased (> 800 x 109 1-').
The clinical course of one of the mesothelioma patients with a
maximum platelet count above 1000 x 109 1-l is shown in Figure 5.
This patient had a reduction of tumour volume of more than 50%
after combination chemotherapy using cisplatin and irinotecan and
achieved a short-lived partial response (PR). Tumour progression
was documented at 5 weeks. The serum IL-6 and CRP levels and
platelet count were high on admission and decreased after the
chemotherapy to a nadir on day 14. Thereafter, the level of serum
IL-6 had increased by day 21, and massive increases in CRP level
andplatelet count were demonstrated. However, the level ofTNF-at
in the serum was never elevated.
Correlation between serum IL-6 levels and survival in
patients with mesothelioma
Survival according to the levels of serum IL-6 in patients with
malignant pleural mesothelioma is shown in Figure 6. There was
no statistically significant difference in survival between the
Table 2 Interleukin 6, acute-phase proteins and adenosine deaminase levels in pleural fluid
IL-6 CRP AGP AAT ADA
Disease (pg ml-') (mgdl-') (mg dl-') (mg dl-') (mgd1')
Malignant pleural mesothelioma (n = 13) 3813 3.1 95 250 13.0
(50.3-49100)11 (0.1-54.2)11 (28-299) (106-470)1 (4.0-35.6)l1
P< 0.05 P< 0.05 NS NS
Lung adenocarcinoma with cytology-positive 359.1 P<O0.05 05 NS 93 NS 194 NS 10.3 P<0.01
pleural effusion (n = 17) (24.6-13532)11 (0.1-4.3) 1 (31-222)1 (109-383)1 (1.6-55.7)11
P < 0.01 P < 0.01 P< 0.01 P< 0.01 P< 0.01
Tuberculous pleurisy (n = 15) 22212 II 2.9 ii 149 ii 280.5 ii 46.5 ii
(1512-138556) (0.3-40.0) (32-263) (164-489) (8.0-70.9)
IL-6, interleukin 6; CRP, C-reactive protein; AGP, alpha-1 acid glycoprotein; AAT, alpha-1 antitrypsin; ADA, adenosine deaminase. Values are expressed as
median (range).
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Figure 4 Correlation between serum IL-6 level and platelet count in patients
with malignant pleural mesothelioma (0) and lung adenocarcinoma and
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Figure 5 Clinical course in the malignant pleural mesothelioma patient with
a maximum platelet count above 1000 x 109 I-'. This patient achieved a
short-lived partial response after combination chemotherapy using cisplatin
and irinotecan; tumour progression was documented at 5 weeks. The serum
IL-6 and CRP levels and platelet count were high on admission and
decreased after the chemotherapy to a nadir on day 14. Thereafter, the level
of serum IL-6 had increased again by day 21, and massive increases of
CRP level and platelet count were also demonstrated. However, the level of
TNF-a in the serum was not elevated
DISCUSSION
One of the characteristic clinical features of malignant pleural
mesothelioma is thrombocytosis, which has been observed at diag-
nosis in about 40% ofpatients and in up to 90% ofpatients during
the clinical course of their disease (Chahinian and Pajak, 1982;
Nakano et al, 1986b; Manzini et al, 1990). IL-6 is known to have a
potent thrombopoietic function (Ishibashi et al, 1989). In this
study, we found a significant correlation between serum IL-6
levels and platelet counts in patients with malignant pleural
mesothelioma, and even higher levels ofIL-6 in the pleural fluid of
patients with tuberculous pleurisy. Both mesothelioma and tuber-
culous pleurisy patients had significantly higherpleural IL-6 levels
and platelet counts than patients with lung adenocarcinoma and
cytology-positive pleural effusion. Pheochromocytoma and
liposarcoma are examples ofIL-6-producing tumours with associ-
ated thrombocytosis (Nagasawa et al, 1990; Suzuki et al, 1991). In
some other diseases, such as rheumatoid arthritis and cardiac
myxoma, and in burmed patients, the elevation of serum IL-6 levels
has also been demonstrated (Holt et al, 1991; Jourdan et al, 1991;
Nijsten et al, 1991).
Several mesothelioma cell lines have been shown to produce IL-
6 (Higashihara et al, 1992; Schmitter et al, 1992; Bielefeldt-
Ohmann et al, 1995a), therefore it is conceivable that large
amounts of IL-6 are produced by the mesothelioma cells in the
thoracic cavity and are persistently released into the systemic
circulation. This could account for the extremely high levels ofIL-
6 in the pleural fluid of our mesothelioma patients and for the
elevated IL-6 levels in the serum. Hirano et al (1981) reported that
T lymphocytes obtained from pleural effusions of patients with
tuberculous pleurisy produced IL-6 when stimulated with PPD.
Activated T lymphocytes could therefore be responsible for IL-6
production and for the extremely high IL-6 levels in the pleural
fluid ofpatients with tuberculous pleurisy.
The APP response is a prominent feature of inflammatory
processes. IL-6 is known to be an important inducer of APPs, but
to regulate albumin levels negatively (Kishimoto, 1989; Akira and
Kishimoto, 1992). We found that serum IL-6 and APP levels in
mesothelioma patients were significantly higher than those in
patients with lung adenocarcinoma with pleural effusion, but that
the difference in pre-albumin levels was not significant. There was
British Journal ofCancer (1998) 77(6), 907-912
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also a significant correlation between serum IL-6 levels and APP
levels. Another study found a statistically significant correlation
between IL-6 and fibrinogen levels in the serum of patients with
head and neck cancer (Gallo et al, 1992). We found very high
levels of APPs in tuberculous pleural fluid similar to those in the
pleural fluid of mesothelioma patients, as well as significantly
increased levels of ADA.
In addition to IL-6, TNF-ox is also implicated in inflammatory
responses. However, in our study, TNF-a could not be detected in
either the pleural fluid or the serum ofmost mesothelioma patients.
This finding is consistent with Monti's observation of high levels
of IL-6 and low levels of TNF-oc in mesothelioma patients (Monti
et al, 1994). Increases in serum TNF-ox levels have rarely been
detected in any cancer patients (Oliff, 1988).
An association between elevated serum IL-6 levels and
decreased survival has been demonstrated in patients with renal
cell carcinoma (Blay et al, 1992) and melanoma (Tartour et al,
1994). Serum IL-6 concentration has therefore been suggested as a
prognostic factor for some malignancies. It has also been reported
that thrombocytosis in patients with malignant mesothelioma is
linked to poor prognosis (Ruffie et al, 1989). However, we could
not find a significant correlation between serum IL-6 levels and
survival in our malignant mesothelioma patients.
IL-6 also plays a significant role in the oncogenesis of certain
malignancies. There is evidence that IL-6 acts as an autocrine
growth factor in multiple myeloma (Kawano et al, 1988), Kaposi's
sarcoma (Miles et al, 1990), non-Hodgkin lymphoma and acute
myeloid leukaemia (Bataille et al, 1989; Yee et al, 1989) although
it has anti-tumour activity in other neoplasms. However, no such
autocrine growth mechanism has been discerned in mesothelioma
cell lines (Akira and Kishimoto, 1992). Nevertheless, IL-6 may
play a role in tumour growth by stimulating angiogenesis (Motro
et al, 1990). In a murine mesothelioma model, Bielefelt-Ohman et
al (1995a) showed that interferon-oc attenuated serum IL-6 levels
and IL-6 mRNA expression in the tumour cells. They also demon-
strated that interferon-o could significantly delay the onset of
clinical manifestations and death in their malignant mesothelioma
model (Bielefelt-Ohman et al, 1995b). A clinical trial of anti-IL-6
therapies for multiple myeloma was reported by Bataille et al, who
showed that a reduction in serum CRP levels and anti-tumorigenic
effects was obtained (Klein et al, 1990). In this study, we found
that the markedly elevated IL-6 and CRP levels in the serum of a
patient with malignant mesothelioma decreased after combination
chemotherapy using cisplatin and irinotecan. The patient achieved
a partial response to the chemotherapy, but this was followed by
early relapse. There were massive increases in the CRP level and
platelet count when the serum IL-6 level again increased after the
nadir. In normal subjects, IL-6 is undetectable in serum or is at a
negligible level. In this patient, however, even the IL-6 level at the
nadir was far higher than the level in normal subjects. The level of
IL-6 showed an increase of 70% over the nadir, which may have
led to rebounds in CRP level and platelet count. The patient's
serum CRP level and platelet count moved in parallel with the
serum IL-6 level. As IL-6 may be involved in clinicopathological
manifestations of malignant pleural mesothelioma, anti-IL-6
therapy is ofinterest for the treatment ofthis neoplasm.
Differentiating malignant pleural mesothelioma from lung
adenocarcinoma with pleural effusion is clinically important to
ensure appropriate therapy, but it is still, however, often difficult.
Immunohistochemical differentiation of the tumours has been
widely investigated using several antibodies. In this study, we have
shown that mesothelioma patients have significantly higher pleural
fluid levels of IL-6 and APP than patients with lung adenocarci-
noma with cytology-positive pleural effusion. These profiles are
not specific to malignant mesothelioma, because similar findings
have been observed in patients with tuberculous pleurisy.
Although there was some overlap in IL-6 levels between mesothe-
lioma and adenocarcinoma with pleural effusion, a detection of
markedly increased levels of IL-6 in the pleural fluid argues
against a diagnosis of adenocarcinoma with pleural effusion, but
the possible confusion with tuberculous pleurisy remains.
In conclusion, malignant mesothelioma patients have large
amounts of IL-6 in the pleural fluid that leak into the systemic
circulation and induce clinical inflammatory reactions. The
increased levels of acute-phase reactants in patients with malig-
nant mesothelioma is an IL-6-related clinical feature.
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